Table 1 Titration of BCLA in different clinical forms of toxoplasmosis
BCLA [UI] | IgG [IU/mL] (Architect) | IgM [index] (Architect) | IgG [IU/mL] (Vidas) | IgM [index] (Vidas) | Clinical context | |
|---|---|---|---|---|---|---|
Serological interpretation | ||||||
Negative | < 65 | < 1.6 | < 0.5 | < 4 | < 0.55 | |
Inconclusive | 65–79 | 1.6–2.9 | 0.50–0.59 | 4–7 | 0.55–0.64 | |
Positive | ≥ 80 | ≥ 3 | ≥ 0.6 | ≥ 8 | ≥ 0.65 | |
Toxoplasma seronegative patients (n = 43) | ||||||
Median [IC25–IC75] | 30.1 [0–57.1] | 0.1 [0–0.1] | 0.09 [0.07–0.14] | / | / | |
Patient 1 | 0 | 0.2 | 0.14 | / | / | Immunocompetent/delivery |
Patient 2 | 37.8 | 0.3 | 0.09 | / | / | Immunocompetent/corneal transplant |
Patient 3 | 115.3 | 0.1 | 0.07 | / | / | Immunocompetent/otitis |
Patient 4 | 69.6 | 0.2 | 0.12 | / | / | Immunosupression/AIDS |
Patient 5 | 16.1 | 0.1 | 0.06 | / | / | Immunocompetent/pregnancy |
Past immunity—chronic toxoplasmosis (n = 79) | ||||||
Median [IC25–IC75] | 102.6 [52.6–171.4] | 29.7 [7.95–69.9] | 0.19 [0.10–0.31] | 132 [41–252] | 0.07 [0.04–0.24] | |
Patient 6 | 61.8 | 22.9 | 0.10 | 101 | 0.03 | Immunocompetent/pregnancy |
Patient 7 | 118.4 | 523 | 0.68 | > 300 | 0.66 | Immunocompetent/pregnancy |
Patient 8 | 180.5 | 26.3 | 0.30 | 120 | 0.27 | Immunosupression/dysglobulinemia |
Patient 9 | 264.9 | 31.6 | 0.41 | 164 | 0.26 | Immunocompetent/pregnancy |
Patient 10 | 77.2 | 68.3 | 0.11 | 199 | 0.11 | Immunocompetent/living kidney donor |
Disseminated toxoplasmosis in immunocompromised patients (n = 9) | ||||||
Median [IC25–IC75] | 127.1 [20.3–294.9] | 28.4 [1.4–269.9] | 0.11 [0.08–0.13] | 42 [2.5–300] | 0.10 [0.04–0.21] | |
Patient 11 | 0 | 1.3 | 0.12 | 2 | 0.24 | Allogeneic HSCT/disseminated toxoplasmosis/positives PCR in BAF, buffy coat and CSF |
Patient 12 | 40.5 | / | / | 42 | 0.17 | Allogeneic HSCT/cerebral toxoplasmosis/positives PCR in buffy coat and CSF |
Patient 13 | 277.4 | 78.8 | 0.11 | > 300 | 0.11 | AIDS/cerebral toxoplasmosis/positives PCR in buffy coat and CSF |
Patient 14 | 127.1 | / | / | > 300 | 0.1 | AIDS/cerebral toxoplasmosis/positive PCR in CSF |
Patient 15 | 213.3 | 28.4 | 0.09 | 25 | 0.03 | Neoplasia/pulmonary toxoplasmosis/positive PCR in BAF |
Asymptomatic serological reactivation in immunocompromised patients (n = 7) | ||||||
Median [IC25–IC75] | 483.7 [190.6–1427.8] | 359.0 [54.7–1254] | 0.86 [0.26–4.93] | 300 [26–300] | 1.33 [0.22–5.26] | |
Patient 16 | 235.1 | 1254 | 0.86 | > 300 | 1.33 | Allogeneic HSCT/3 negative PCR in buffy coat |
Patient 17 | 701.8 | 936.4 | 0.26 | > 300 | 0.04 | Allogeneic HSCT |
Patient 18 | 1427.8 | 359.0 | 2.68 | > 300 | 2.76 | Allogeneic HSCT/2 negative PCR in buffy coat |
Patient 19 | 173.8 | > 2000 | 0.17 | > 300 | 0.26 | Allogeneic HSCT |
Patient 20 | 190.6 | 107.1 | 6.18 | 23 | 5.26 | Allogeneic HSCT/2 negative PCR in buffy coat |
Ocular toxoplasmosis (n = 18) | ||||||
Median [IC25–IC75] | 117.7 [47.1–227.9] | 87.7 [25.6–405.5] | 0.21 [0.09–1.53] | 199 [135–300] | 0.09 [0.04–0.86] | |
Patient 21 | 46.6 | / | / | 264 | 0.10 | Immunosuppression/positive PCR in AH |
Patient 22 | 167.7 | 71.5 | 0.22 | 178 | 0.14 | Immunocompetent/positive PCR in AH |
Patient 23 | 1622.2 | > 2000 | 0.15 | > 300 | 0.11 | Immunocompetent/positive PCR in AH |
Patient 24 | 75.5 | 11 | 0.09 | 48 | 0.04 | Immunocompetent/production of antibodies in HA |
Patient 25 | 193 | 370.8 | 9.01 | 209 | 4.99 | Immunocompetent/production of antibodies in HA |